BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 16, 2024
See today's BioWorld
Home
» Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy
Nov. 22, 2011
By
Marie Powers
No Comments
Thanksgiving came early for Pharmasset Inc. with the news that Gilead Sciences Inc. will gobble it up in a deal valued at $11 billion.
BioWorld
